江西长江药业有限公司
- Country
- Ownership
- -
- Established
- 1994-09-16
- Employees
- -
- Market Cap
- -
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
39
NMPA:39
Drug Approvals
Compound Sodium Chloride Injection
- Product Name
- 复方氯化钠注射液
- Approval Number
- 国药准字H36021269
- Approval Date
- Jul 18, 2022
NMPA
Diprophylline and Sodium Chloride Injection
- Product Name
- 二羟丙茶碱氯化钠注射液
- Approval Number
- 国药准字H20040794
- Approval Date
- Jul 17, 2022
NMPA
Glucose and Sodium Chloride Injection
- Product Name
- 葡萄糖氯化钠注射液
- Approval Number
- 国药准字H36021274
- Approval Date
- Jul 17, 2022
NMPA
Inosine and Sodium Chloride Injection
- Product Name
- 泽贝
- Approval Number
- 国药准字H20020313
- Approval Date
- Jul 17, 2022
NMPA
Glucose and Sodium Chloride Injection
- Product Name
- 葡萄糖氯化钠注射液
- Approval Number
- 国药准字H36022233
- Approval Date
- Jul 17, 2022
NMPA
Ciprofloxacin Lactate and Sodium Chloride Injection
- Product Name
- 乳酸环丙沙星氯化钠注射液
- Approval Number
- 国药准字H20023269
- Approval Date
- Jul 17, 2022
NMPA
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
No trials found
News
No news found